Marta Scorsetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7334113/publications.pdf

Version: 2024-02-01

295	9,215	46918	66788
papers	citations	47 h-index	78 g-index

297	297	297	9220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncology, The, 2020, 21, e18-e28.	5.1	588
2	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.3	352
3	Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1166-1175.	2.5	302
4	Thymoma and thymic carcinomas. Critical Reviews in Oncology/Hematology, 2016, 99, 332-350.	2.0	220
5	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	1.9	185
6	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 336-342.	0.4	168
7	On the pre-clinical validation of a commercial model-based optimisation engine: Application to volumetric modulated arc therapy for patients with lung or prostate cancer. Radiotherapy and Oncology, 2014, 113, 385-391.	0.3	157
8	Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 543-553.	1.2	145
9	Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiotherapy and Oncology, 2013, 107, 414-418.	0.3	141
10	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). Journal of Cancer Research and Clinical Oncology, 2015, 141, 1301-1309.	1.2	135
11	Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 313-322.	0.4	134
12	Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. Journal of Neuro-Oncology, 2017, 135, 129-139.	1.4	116
13	Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiation Oncology, 2011, 6, 113.	1.2	107
14	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology, 2013, 8, 171.	1.2	98
15	Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiotherapy and Oncology, 2018, 129, 427-434.	0.3	98
16	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiation Oncology, 2013, 8, 148.	1.2	91
17	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer, 2014, 14, 619.	1.1	86
18	A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers. Radiation Oncology, 2015, 10, 220.	1.2	85

#	Article	IF	Citations
19	Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. European Journal of Cancer, 2015, 51, 668-674.	1.3	83
20	Clinical Outcome of Hypofractionated Stereotactic Radiotherapy for Abdominal Lymph Node Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 81, 831-838.	0.4	81
21	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiation Oncology, 2014, 9, 91.	1.2	81
22	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technology in Cancer Research and Treatment, 2017, 16, 295-301.	0.8	80
23	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer, 2017, 17, 829.	1.1	77
24	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta OncolÃ³gica, 2012, 51, 618-623.	0.8	76
25	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1155-1164.	3.3	76
26	Cranio-spinal irradiation with volumetric modulated arc therapy: A multi-institutional treatment experience. Radiotherapy and Oncology, 2011, 99, 79-85.	0.3	73
27	Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study. Lung Cancer, 2014, 84, 248-253.	0.9	73
28	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5â€‰years of follow-up. Radiation Oncology, 2018, 13, 234.	1.2	73
29	Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiation Oncology, 2012, 7, 145.	1.2	72
30	Volumetric Modulation Arc Radiotherapy Compared With Static Gantry Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma Tumor: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 942-949.	0.4	71
31	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
32	Preclinical Assessment of Volumetric Modulated Arc Therapy for Total Marrow Irradiation. International Journal of Radiation Oncology Biology Physics, 2011, 80, 628-636.	0.4	68
33	RapidPlan head and neck model: the objectives and possible clinical benefit. Radiation Oncology, 2017, 12, 73.	1.2	66
34	Stereotactic body radiation therapy for liver metastases. Journal of Gastrointestinal Oncology, 2014, 5, 190-7.	0.6	66
35	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiation Oncology, 2016, 11, 76.	1.2	59
36	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	1.1	58

#	Article	IF	Citations
37	Applying failure mode effects and criticality analysis in radiotherapy: Lessons learned and perspectives of enhancement. Radiotherapy and Oncology, 2010, 94, 367-374.	0.3	57
38	Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiation Oncology, 2012, 7, 16.	1.2	57
39	Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncology, The, 2020, 21, e477-e487.	5.1	57
40	Critical Appraisal of Volumetric Modulated Arc Therapy in Stereotactic Body Radiation Therapy for Metastases to Abdominal Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1570-1577.	0.4	56
41	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist, 2020, 25, e311-e320.	1.9	56
42	Performance of a Knowledge-Based Model for Optimization of Volumetric Modulated Arc Therapy Plans for Single and Bilateral Breast Irradiation. PLoS ONE, 2015, 10, e0145137.	1.1	55
43	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	2.0	52
44	Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLoS ONE, 2014, 9, e95303.	1.1	52
45	Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results. Acta OncolÃ³gica, 2011, 50, 528-538.	0.8	51
46	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast, 2016, 26, 11-17.	0.9	51
47	Dosimetric trade-offs in breast treatment with VMAT technique. British Journal of Radiology, 2017, 90, 20160701.	1.0	51
48	Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. Medical Physics, 2012, 39, 1112-1118.	1.6	49
49	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiotherapy and Oncology, 2019, 133, 220-226.	0.3	49
50	Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clinical Oncology, 2016, 28, 13-20.	0.6	47
51	Checkpoint inhibitors as treatment for malignant gliomas: â€œA long way to the topâ€• Cancer Treatment Reviews, 2018, 69, 121-131.	3.4	46
52	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critical Reviews in Oncology/Hematology, 2012, 84, 101-108.	2.0	44
53	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. Journal of Urology, 2019, 201, 70-76.	0.2	44
54	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiotherapy and Oncology, 2020, 148, 194-200.	0.3	43

#	Article	IF	Citations
55	Accuracy evaluation of fusion of CT, MR, and SPECT images using commercially available software packages (SRS PLATO and IFS). International Journal of Radiation Oncology Biology Physics, 1999, 43, 227-234.	0.4	42
56	Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiotherapy and Oncology, 2014, 112, 425-429.	0.3	42
57	Stereotactic Body Radiation Therapy (SBRT) for adrenal metastases. Strahlentherapie Und Onkologie, 2011, 187, 238-244.	1.0	41
58	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.3	40
59	Re-irradiation of metastatic spinal cord compression: A feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canal. Radiotherapy and Oncology, 2010, 94, 67-70.	0.3	39
60	Pretreatment quality assurance of flattening filter free beams on 224 patients for intensity modulated plans: A multicentric study. Medical Physics, 2012, 39, 1351-1356.	1.6	39
61	Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 990-996.	1.0	39
62	Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiation Oncology, 2012, 7, 204.	1.2	38
63	Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience. European Spine Journal, 2012, 21, 146-148.	1.0	38
64	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. British Journal of Radiology, 2015, 88, 20140736.	1.0	38
65	Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. Radiation Oncology, 2016, 11, 120.	1.2	38
66	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treatment Reviews, 2018, 71, 76-87.	3.4	38
67	Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). Journal of Neuro-Oncology, 2019, 142, 59-67.	1.4	37
68	Percutaneous Vertebral Augmentation in Metastatic Disease: State of the Art. The Journal of Supportive Oncology, 2011, 9, 4-10.	2.3	36
69	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlentherapie Und Onkologie, 2019, 195, 805-818.	1.0	36
70	Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiation Oncology, 2010, 5, 93.	1.2	35
71	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. International Journal of Gynecological Cancer, 2018, 28, 1507-1513.	1.2	35
72	Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiation Oncology, 2010, 5, 94.	1.2	34

#	Article	IF	Citations
73	Cone beam CT preâ€•and postâ€‘daily treatment for assessing geometrical and dosimetric intrafraction variability during radiotherapy of prostate cancer. Journal of Applied Clinical Medical Physics, 2011, 12, 141-152.	0.8	34
74	Interplay effects between dose distribution quality and positioning accuracy in total marrow irradiation with volumetric modulated arc therapy. Medical Physics, 2013, 40, 111713.	1.6	34
75	Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. Physica Medica, 2015, 31, 677-682.	0.4	34
76	Accuracy evaluation of the optical surface monitoring system on EDGE linear accelerator in a phantom study. Medical Dosimetry, 2016, 41, 173-179.	0.4	34
77	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Research and Treatment, 2017, 49, 20-28.	1.3	34
78	Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation. Radiation Oncology, 2018, 13, 122.	1.2	34
79	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1399-1407.	3.3	33
80	Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2016, 50, 1077-1082.	0.6	33
81	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Lowâ€“Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	0.6	33
82	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. European Journal of Surgical Oncology, 2017, 43, 735-742.	0.5	33
83	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology and Hepatology, 2020, 5, 765-775.	3.7	33
84	Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model. Radiologia Medica, 2021, 126, 1619-1656.	4.7	33
85	High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid. Oncologist, 2009, 14, 548-556.	1.9	32
86	Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. Acta OncolÃ³gica, 2013, 52, 545-552.	0.8	32
87	Evaluation of the dose calculation accuracy for small fields defined by jaw or MLC for AAA and Acuros XB algorithms. Medical Physics, 2016, 43, 5685-5694.	1.6	32
88	Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiation Oncology, 2014, 9, 18.	1.2	31
89	Hypofractionated stereotactic radiation therapy in skull base meningiomas. Journal of Neuro-Oncology, 2015, 124, 283-289.	1.4	31
90	Role of Surgical Resection in Patients with Single Large Brain Metastases: Feasibility, Morbidity, and Local Control Evaluation. World Neurosurgery, 2016, 94, 6-12.	0.7	31

#	Article	IF	Citations
91	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	1.2	31
92	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treatment Reviews, 2016, 50, 1-8.	3.4	30
93	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 111-121.	0.4	30
94	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	3.4	30
95	Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy. Annals of Surgical Oncology, 2016, 23, 3040-3046.	0.7	29
96	Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 785-793.	0.4	29
97	Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults. International Journal of Radiation Oncology Biology Physics, 2018, 100, 17-20.	0.4	29
98	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Medicine, 2018, 7, 4379-4386.	1.3	29
99	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: aÂmulti-institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 213-221.	1.0	29
100	Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2012, 188, 49-55.	1.0	28
101	Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1777-1783.	1.2	28
102	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiation Oncology, 2013, 8, 176.	1.2	27
103	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. Expert Review of Anticancer Therapy, 2016, 16, 731-740.	1.1	27
104	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. World Journal of Surgery, 2018, 42, 2651-2659.	0.8	27
105	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	1.2	27
106	Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. Acta OncolÃ³gica, 2020, 59, 1224-1234.	0.8	27
107	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	2.0	27
108	Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. European Radiology, 2021, 31, 4079-4086.	2.3	27

#	Article	IF	Citations
109	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. Journal of Applied Clinical Medical Physics, 2012, 13, 138-147.	0.8	26
110	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1293-1299.	1.2	26
111	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. Radiation Oncology, 2017, 12, 200.	1.2	26
112	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. Technology in Cancer Research and Treatment, 2018, 17, 153303381880388.	0.8	26
113	Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases. International Journal of Colorectal Disease, 2010, 25, 1435-1439.	1.0	25
114	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	2.0	25
115	Evaluation of a synthetic singleâ€crystal diamond detector for relative dosimetry on the Leksell Gamma Knife Perfexion radiosurgery system. Medical Physics, 2015, 42, 5035-5041.	1.6	25
116	New Perspectives in the Treatment of Colorectal Metastases. Liver Cancer, 2017, 6, 90-98.	4.2	25
117	Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. Medical Oncology, 2019, 36, 48.	1.2	25
118	Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma. Current Oncology Reports, 2020, 22, 91.	1.8	25
119	Flattening filter free beams from TrueBeam and Versa HD units: Evaluation of the parameters for quality assurance. Medical Physics, 2015, 43, 205-212.	1.6	24
120	Organs at risk in lung SBRT. Physica Medica, 2017, 44, 131-138.	0.4	24
121	On the <scp>gEUD</scp> biological optimization objective for organs at risk in Photon Optimizer of Eclipse treatment planning system. Journal of Applied Clinical Medical Physics, 2018, 19, 106-114.	0.8	24
122	Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1307-1313.	1.2	24
123	Imaging biomarkers in primary brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 597-612.	3.3	23
124	SBRT for prostate cancer: Challenges and features from a physicist prospective. Physica Medica, 2016, 32, 479-484.	0.4	23
125	Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 6-11.	0.6	23
126	Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain Metastases. PLoS ONE, 2016, 11, e0157869.	1.1	23

#	Article	IF	Citations
127	Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases. Anticancer Research, 2009, 29, 4259-63.	0.5	23
128	Vertebroplasty for pain relief and spinal stabilization in multiple myeloma. Neurological Sciences, 2010, 31, 151-157.	0.9	22
129	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 224.	1.2	22
130	Characterization of a new unshielded diode for small field dosimetry under flattening filter free beams. Physica Medica, 2016, 32, 408-413.	0.4	22
131	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 614-621.	0.4	22
132	Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Research, 2013, 33, 4537-43.	0.5	22
133	Multimodal Approach to the Management of Metastatic Epidural Spinal Cord Compression (MESCC) Due to Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1467-1473.	0.4	21
134	Expression of the Transcription Factor HEY1 in Glioblastoma: A Preliminary Clinical Study. Tumori, 2010, 96, 97-102.	0.6	21
135	Sporadic endolymphatic sac tumor: Its clinical, radiological, and histological features, management, and followâ€up. Head and Neck, 2013, 35, 1043-1047.	0.9	21
136	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. BMC Cancer, 2015, 15, 486.	1.1	21
137	Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Reports of Practical Oncology and Radiotherapy, 2015, 20, 417-424.	0.3	21
138	Collimator angle influence on dose distribution optimization for vertebral metastases using	1.6	20
139	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1795-1800.	1.2	20
140	Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. Journal of Neuro-Oncology, 2017, 131, 377-384.	1.4	20
141	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. European Urology Focus, 2021, 7, 241-244.	1.6	20
142	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. BMC Cancer, 2014, 14, 833.	1.1	19
143	In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study. Radiation Oncology, 2015, 10, 86.	1.2	19
144	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlentherapie Und Onkologie, 2020, 196, 325-333.	1.0	19

#	Article	IF	Citations
145	Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge. Cancer Research and Treatment, 2016, 48, 37-44.	1.3	19
146	Design and characterization of a dynamic multileaf collimator. Physics in Medicine and Biology, 1998, 43, 3149-3155.	1.6	18
147	Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy. BMC Cancer, 2016, 16, 362.	1.1	18
148	Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. Acta Neurochirurgica, 2018, 160, 1779-1787.	0.9	18
149	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiotherapy and Oncology, 2018, 127, 326-331.	0.3	17
150	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with â€œcurativeâ€•intent. Lung Cancer, 2020, 141, 1-8.	0.9	17
151	Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. Neurosurgical Focus, 2020, 49, E10.	1.0	17
152	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	0.6	16
153	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. Oncotarget, 2017, 8, 67696-67708.	0.8	16
154	Total monitor units influence on plan quality parameters in volumetric modulated arc therapy for breast case. Physica Medica, 2014, 30, 296-300.	0.4	15
155	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. British Journal of Radiology, 2015, 88, 20150111.	1.0	15
156	Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. Radiotherapy and Oncology, 2018, 127, 108-113.	0.3	15
157	Consensus Report From the Miami Liver Proton Therapy Conference. Frontiers in Oncology, 2019, 9, 457.	1.3	15
158	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.4	15
159	Does deep inspiration breath hold reduce plan complexity? Multicentric experience of left breast cancer radiotherapy with volumetric modulated arc therapy. Physica Medica, 2019, 59, 79-85.	0.4	15
160	Preliminary Results of a Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). Clinical Breast Cancer, 2021, 21, 231-238.	1.1	15
161	Semiautomatic technique for defining the internal gross tumor volume of lung tumors close to	1.6	14
162	Vertebral metastases reirradiation with volumetric-modulated arc radiotherapy. Radiotherapy and Oncology, 2012, 102, 416-420.	0.3	14

#	Article	IF	Citations
163	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 163-169.	0.3	14
164	Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1301-1309.	1.2	14
165	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. Cancer Investigation, 2017, 35, 586-593.	0.6	14
166	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14
167	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast, 2018, 42, 31-37.	0.9	14
168	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	1.2	14
169	Technical Note: Flattening filter free beam from Halcyon linac: Evaluation of the profile parameters for quality assurance. Medical Physics, 2020, 47, 3669-3674.	1.6	14
170	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkinâ€™s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	1.2	14
171	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 2021, 38, 527-537.	1.7	14
172	Laparoscopic debulking of bulky lymph nodes in women with cervical cancer: indication and surgical outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 688-692.	1.1	13
173	Surgery Followed by Radiotherapy for the Treatment of Metastatic Epidural Spinal Cord Compression From Breast Cancer. Spine, 2011, 36, E1352-E1359.	1.0	13
174	Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma. Reports of Practical Oncology and Radiotherapy, 2012, 17, 262-268.	0.3	13
175	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. British Journal of Radiology, 2017, 90, 20170422.	1.0	13
176	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. World Neurosurgery, 2017, 105, 184-190.	0.7	13
177	Small field characterization of a Nanochamber prototype under flattening filter free photon beams. Physica Medica, 2018, 49, 139-146.	0.4	13
178	Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiation Oncology, 2020, 15, 120.	1.2	13
179	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	0.8	13
180	Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. Radiotherapy and Oncology, 2022, 167, 89-96.	0.3	13

#	Article	IF	Citations
181	Stereotactic radiosurgery for patients with brain metastases. Lancet Oncology, The, 2014, 15, e246-e247.	5.1	12
182	Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions. British Journal of Radiology, 2015, 88, 20150468.	1.0	12
183	Use of PTW-microDiamond for relative dosimetry of unflattened photon beams. Physica Medica, 2017, 38, 45-53.	0.4	12
184	AÂradiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.. Strahlentherapie Und Onkologie, 2020, 196, 922-931.	1.0	12
185	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2289-2297.	1.2	12
186	Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. British Journal of Radiology, 2020, 93, 20200250.	1.0	12
187	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatmentâ€™s intensification?. Radiotherapy and Oncology, 2020, 150, 184-190.	0.3	12
188	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. Acta OncolÃ³gica, 2014, 53, 990-992.	0.8	11
189	Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori, 2019, 105, 47-54.	0.6	11
190	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	4.7	11
191	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. Laryngoscope, 2020, 130, E163-E170.	1.1	11
192	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. British Journal of Radiology, 2020, 93, 20190627.	1.0	11
193	Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis. Clinical Breast Cancer, 2020, 20, 527-533.	1.1	11
194	Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost. Radiotherapy and Oncology, 2021, 164, 50-56.	0.3	11
195	Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Solid Tumors Submitted for Surgery Followed by Radiation Therapy. World Neurosurgery, 2018, 115, e681-e687.	0.7	10
196	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncology, 2019, 15, 3775-3782.	1.1	10
197	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 480-486.	1.1	10
198	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 885.	1.7	10

#	Article	IF	Citations
199	Development of an Immobilization Device for Total Marrow Irradiation. Practical Radiation Oncology, 2021, 11, e98-e105.	1.1	10
200	Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). ESMO Open, 2021, 6, 100188.	2.0	10
201	Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. Tumori, 2015, 101, 174-178.	0.6	9
202	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.3	9
203	Stereotactic Radiotherapy for Parasagittal and Parafalcine Meningiomas: Patient Selection and Special Considerations . Cancer Management and Research, 2019, Volume 11, 10051-10060.	0.9	9
204	MLC parameters from static fields to VMAT plans: an evaluation in a RT-dedicated MC environment (PRIMO). Radiation Oncology, 2019, 14, 216.	1.2	9
205	Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?. Oncologist, 2020, 25, e1249-e1250.	1.9	9
206	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. Clinical and Experimental Metastasis, 2020, 37, 565-573.	1.7	9
207	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.3	9
208	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2021, 147, 927-936.	1.2	9
209	Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis. Clinical and Experimental Metastasis, 2021, 38, 511-518.	1.7	9
210	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. Nuclear Medicine Communications, 2018, 39, 951-956.	0.5	8
211	Equipment, staffing, and provision of radiotherapy in Lombardy, Italy: Results of three surveys performed between 2012 and 2016. Tumori, 2018, 104, 352-360.	0.6	8
212	Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. PLoS ONE, 2018, 13, e0201992.	1.1	8
213	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. British Journal of Radiology, 2019, 92, 20190252.	1.0	8
214	Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. Future Oncology, 2020, 16, 269-279.	1.1	8
215	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 608-616.	1.0	8
216	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. Strahlentherapie Und Onkologie, 2021, 197, 396-404.	1.0	8

#	Article	IF	Citations
217	Knowledge-based intensity-modulated proton planning for gastroesophageal carcinoma. Acta OncolÃ³gica, 2021, 60, 285-292.	0.8	8
218	Brain metastases from primary colorectal cancer: is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO). British Journal of Radiology, 2020, 93, 20200951.	1.0	8
219	Can magnetic resonance image-guided focused ultrasound surgery replace local oncology treatments? A review. Tumori, 2011, 97, 259-64.	0.6	8
220	Intramedullary astrocytoma with granular cell differentiation. Neurosurgical Review, 2007, 30, 339-343.	1.2	7
221	11C Choline PET Guided Salvage Radiotherapy with Volumetric Modulation Arc Therapy and Hypofractionation for Recurrent Prostate Cancer after HIFU Failure: Preliminary Results of Tolerability and Acute Toxicity. TCRT Express, 2013, 13, 395-401.	1.5	7
222	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. World Neurosurgery, 2019, 123, e273-e279.	0.7	7
223	Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2267-2276.	1.2	7
224	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. European Journal of Cancer, 2021, 143, 75-77.	1.3	7
225	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. Lung Cancer, 2021, 152, 1-6.	0.9	7
226	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplantation and Cellular Therapy, 2021, 27, 492.e1-492.e6.	0.6	7
227	Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. Journal of Clinical Medicine, 2021, 10, 2313.	1.0	7
228	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIROâ€Head and Neck working group. Oral Diseases, 2022, 28, 345-351.	1.5	7
229	Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-644.	0.6	7
230	Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-44.	0.6	7
231	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	1.0	6
232	Gantry-Mounted Linear Acceleratorâ€"Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411.	0.6	6
233	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 628-635.	0.6	6
234	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlentherapie Und Onkologie, 2021, 197, 133-140.	1.0	6

#	Article	IF	Citations
235	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
236	Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. Anticancer Research, 2017, 37, 7057-7062.	0.5	6
237	Reirradiation: Hopes and Concerns of the Radiation Oncologist. Tumori, 2010, 96, 792-793.	0.6	5
238	Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment. Reports of Practical Oncology and Radiotherapy, 2015, 20, ix-x.	0.3	5
239	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. British Journal of Radiology, 2017, 90, 20170022.	1.0	5
240	Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Breast Cancer Treated with Surgery Followed by Radiotherapy. World Neurosurgery, 2018, 110, e281-e286.	0.7	5
241	Back to (new) normalityâ€"A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108.	1.2	5
242	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	1.2	5
243	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3619-3625.	1.2	5
244	Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. Journal of Neurosurgery, 2020, 135, 64-77.	0.9	5
245	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. Strahlentherapie Und Onkologie, 2022, 198, 710-718.	1.0	5
246	Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patientsâ€™ selection. Clinical and Experimental Metastasis, 2022, 39, 449-457.	1.7	5
247	Hypofractionation in current clinical practice: a flash forward to the near future of radiation oncology?. Tumori, 2012, 98, 395-7.	0.6	5
248	Does Tumor Volume Have a Prognostic Role in Oropharyngeal Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 2465.	1.7	5
249	Postoperative Radiotherapy in Prostate Cancer: Acquired Certainties and Still Open Issues. A Review of Recent Literature. Tumori, 2011, 97, 1-8.	0.6	4
250	Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. British Journal of Radiology, 2018, 91, 20170634.	1.0	4
251	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. British Journal of Radiology, 2019, 92, 20181026.	1.0	4
252	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. Clinical Lung Cancer, 2020, 21, 86-93.	1.1	4

#	Article	IF	Citations
253	Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer. Oncologist, 2021, 26, e1085-e1086.	1.9	4
254	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. Practical Radiation Oncology, 2021, 11, e329-e338.	1.1	4
255	Discrepancies between UICC and AJCC TNM classifications for oral cavity tumors in the 8th editions and following versions. European Archives of Oto-Rhino-Laryngology, 2022, 279, 527-531.	0.8	4
256	Conformal and stereotactic radiotherapy in hepatocellular carcinoma. Annali Italiani Di Chirurgia, 2008, 79, 107-10.	0.1	4
257	Reirradiation: hopes and concerns of the radiation oncologist. Tumori, 2010, 96, 792-3.	0.6	4
258	Neoadjuvant Chemoradiotherapy with Volumetric-modulated Arc Therapy for Medium-distal Oesophageal and Gastro-oesophageal Junction Carcinoma. Anticancer Research, 2015, 35, 4109-16.	0.5	4
259	Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patientâ€level data from 4 prospective trials. Cancer, 2022, 128, 2367-2374.	2.0	4
260	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. Clinical and Experimental Metastasis, 2022, 39, 443.	1.7	4
261	Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis. Tumori, 2012, 98, 31e-34e.	0.6	4
262	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiotherapy and Oncology, 2022, 172, 1-9.	0.3	4
263	Semiautomatic method to identify the best phase for gated RT in lung region by 4Dâ€PET/CT acquisitions. Medical Physics, 2011, 38, 354-362.	1.6	3
264	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1937-1945.	1.2	3
265	Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). Journal of Cancer Research and Clinical Oncology, 2021, 147, 2069-2077.	1.2	3
266	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. Reports of Practical Oncology and Radiotherapy, 2021, 26, 101-110.	0.3	3
267	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.3	3
268	Charlson comorbidity index and G8 in older old adult(â‰¥80Âyears) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. Journal of Geriatric Oncology, 2021, 12, 1100-1103.	0.5	3
269	Could Single-high-dose Radiotherapy be Considered the New Frontier of Stereotactic Ablative Radiation Therapy?. Tumori, 2014, 100, e92-e93.	0.6	3
270	Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. Tumori, 2012, 98, 67e-71e.	0.6	3

#	Article	IF	Citations
271	The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technology in Cancer Research and Treatment, 2020, 19, 153303382098041.	0.8	2
272	The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. Radiotherapy and Oncology, 2021, 156, 49-55.	0.3	2
273	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	0.6	2
274	A reply to â€œmanaging oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapyâ€. Lung Cancer, 2021, 157, 165-166.	0.9	2
275	Could single-high-dose radiotherapy be considered the new frontier of stereotactic ablative radiation therapy?. Tumori, 2014, 100, e92-3.	0.6	2
276	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. Acta OncolÃ³gica, 2022, 61, 553-559.	0.8	2
277	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. Expert Review of Anticancer Therapy, 2020, 20, 743-753.	1.1	1
278	Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. CNS Oncology, 2017, 6, 211-219.	1.2	1
279	How I faced my prostate cancer: a molecular biologistâ€™s perspective. Npj Precision Oncology, 2021, 5, 88.	2.3	1
280	Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma. Anticancer Research, 2016, 36, 3451-7.	0.5	1
281	Skull Base Meningiomas: Is Surgical Resection Enough? Outcome Evaluation and Prognostic Factors Analysis in a Single-Center Cohort. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2022, 83, 516-522.	0.4	1
282	Bronchoscopically-guided conformal radiation therapy for radiographically occult lung carcinoma. Radiotherapy and Oncology, 2001, 58, 269-271.	0.3	0
283	Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. Journal of Neuro-Oncology, 2007, 81, 323-325.	1.4	0
284	In Response to Dr. Russi and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279-1280.	0.4	0
285	Reply to the Letter to the editor on Cranio-spinal irradiation with volumetric modulated arc therapy by G. Saini et al.. Radiotherapy and Oncology, 2012, 102, 322-323.	0.3	0
286	Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls. Radiotherapy and Oncology, 2012, 105, 271.	0.3	0
287	Relationship Between Molecular Oncology and Radiotherapy in Malignant Gliomas (An Overview). , 2012, , 103-110.		0
288	Reply to Dr. Maluta and Colleagues. Tumori, 2012, 98, 172-173.	0.6	0

#	Article	IF	Citations
289	Solitary Brain Metastasis from Non-Small Cell Lung Cancer. , 2014, , 131-139.		0
290	Reply to the letter to the editor â€œIntegration of methionine-PET into the radiotherapy planning process for high grade glioma: Prospects against non-central and central failuresâ€, by S. Revannasiddaiah et al.. Radiotherapy and Oncology, 2014, 113, 297.	0.3	0
291	Role of Radiotherapy in Malignant Pleural Mesothelioma. , 2019, , 205-220.		0
292	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. Cancer Management and Research, 2021, Volume 13, 7009-7031.	0.9	0
293	Response to letter to the editor regarding C Franzese et al. â€œMetastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancerâ€. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	0
294	High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.. Journal of Clinical Oncology, 2019, 37, e13512-e13512.	0.8	0
295	Response Assessment and Follow-Up by Imaging in Breast Tumors. Medical Radiology, 2020, , 451-474.	0.0	0